Health Canada's New Enforcement Policy Is Already in Force: What POL-0001 Version 10 Changes for Every Licence Holder

On 15 September 2026, Health Canada's compliance and enforcement policy for health products, known as POL-0001, came into effect the same day it was published. It replaces version 9, and there is no transition period. If your inspection-response and CAPA procedures still cite the old version, they now reference a superseded policy, and the gap is the kind an inspector notices.

Version 10 is not a cosmetic refresh. It restates, in one place, the full range of actions Health Canada can take against a licence holder, from a guidance letter to a referral for prosecution. It also names the product classes in scope more broadly than most companies expect. This article explains what changed, who is now covered, the graduated enforcement ladder, the penalty structure under the Food and Drugs Act, and the eleven documents you should re-verify. It pairs closely with our Health Canada inspection-readiness self-assessment and our guide to everything that changes on 1 October 2026.

Executive Summary

POL-0001 version 10 is Health Canada's national compliance and enforcement policy for health products. It took effect 15 September 2026 and replaces version 9. It expressly names seven product classes in scope, including biocides, natural health products, and veterinary drugs and veterinary health products, alongside human drugs, medical devices, blood and blood components, and cells, tissues and organs. It groups Health Canada's tools into three categories, compliance promotion, compliance monitoring, and enforcement, and confirms that responses graduate toward stronger action when non-compliance persists. Penalties for therapeutic product offences reach up to $5,000,000 on indictment under section 31.2, with higher exposure under section 31.4 where a person knowingly or recklessly causes a serious risk of injury. Every licence holder should re-map its inspection-response, CAPA, and recall procedures against the version 10 language now, not after an inspection.

What POL-0001 is

POL-0001 is Health Canada's policy describing how it promotes, monitors and enforces compliance with the Food and Drugs Act and its regulations for health products. It is administered by the Regulatory Operations and Enforcement Branch, known as ROEB, the dedicated compliance and enforcement branch within Health Canada. The policy is administrative: it does not override the Act or the regulations, but it tells regulated parties how Health Canada will exercise its authorities.

Why it matters: POL-0001 is the single document that sets your expectations for how you will be inspected, what an inspector can ask for, and what happens if you fall short. What to do: read version 10 in full, confirm the version your quality system references, and update any procedure that still points to version 9.

What changed on 15 September 2026

Version 10 restructures the policy into a web-based format with distinct sections for the overview, roles and responsibilities, guiding principles, the actions and tools, a glossary and references. More importantly for compliance teams, it states the product scope expressly and sets out the three categories of action with a clear statement that enforcement graduates when non-compliance persists.

Who is in scope now

The policy applies to compliance and enforcement activities for health products and activities regulated under the Act. What it means for you: if you hold an establishment licence, a site licence, a product authorization, a DIN or an NPN in any of the classes below, this policy governs how you are overseen. What to do: confirm your sector is named, because biocides, veterinary health products, blood and cells, tissues and organs are now expressly listed.

For biocide manufacturers and importers, this is the second regulatory signal in a year, following the biocide transition and recall obligations we cover in our biocide recall guidance. For natural health product firms, it sits on top of the summary reports and site-licence scope obligations already in play.

The three categories: promotion, monitoring and enforcement

Version 10 groups every tool into three categories. Compliance promotion is education: Health Canada publishes guidance, raises awareness of the actions it can take, and informs consumers. Compliance monitoring is verification: inspections tied to establishment and site licences, product sampling, laboratory analysis, and the gathering of complaints, recalls, shortage reports, incident reports and information shared by foreign regulators. Enforcement is the response when requirements are not met.

Why it matters: the same inspection can move from monitoring to enforcement in a single visit. What to do: treat every inspection, sample request and records request as a monitoring activity that can escalate, and prepare your team to respond to each professionally and on time.

The enforcement escalation ladder

Health Canada chooses a response proportionate to the health and safety risk. Sometimes the risk warrants an immediate measure such as a licence suspension, an injunction or a referral for prosecution. Other times the regulated party is given an opportunity to come into compliance. If non-compliance persists, the actions taken may graduate toward stronger measures. The ladder below runs from lightest to heaviest intervention.

• Compliance promotion: guidance, awareness of enforcement tools, and consumer information
• Compliance monitoring: inspections, product sampling, laboratory analysis and information gathering
• Risk communication: public advisories and other risk communications
• Adding or amending terms and conditions on an establishment licence or product authorization
• Requesting a plan for corrective and preventive measures in an inspection or a proposed suspension
• Requesting a stop sale or recall, or ordering a recall of a therapeutic product
• Border action: recommending that the Canada Border Services Agency refuse entry, or seizing, removing or destroying goods at the border
• Seizing and detaining product
• Refusing, suspending, cancelling or revoking a licence, authorization or registration
• Seeking a court injunction under section 21.5(1) of the Act
• Conducting an investigation and referring the matter to the Public Prosecution Service of Canada for prosecution

The penalty structure: sections 31, 31.2 and 31.4

What it is: the Food and Drugs Act sets out the offences and penalties that sit at the top of the ladder. What it means: the ceiling depends on whether the offence relates to a therapeutic product and whether it was committed knowingly or recklessly. What to do: quote the correct section, because the therapeutic product ceiling under section 31.2 is a thousand times higher than the general ceiling under section 31.

Sections 31 and 31.2 are strict liability offences, so a due diligence defence is available where the regulated party can show it took reasonable steps to meet the Act. Section 31.4 is a mens rea offence, which the Public Prosecution Service of Canada must prove. For the mandatory reporting and recall powers that feed these provisions, see our explainer on Vanessa's Law.

Procedural fairness: what you are entitled to

Regulated parties subject to a regulatory action or decision can expect Health Canada to adhere to procedural fairness principles and to be given a reasonable opportunity to be heard. What it means: an adverse decision is not the end of the conversation, and your response is part of the record. What to do: keep a documented, factual response process so that when you are given the opportunity to be heard, you can present evidence quickly and credibly.

Why version 10 matters more if you hold licences in several classes

What it is: a single policy that now applies, in identical terms, across seven product classes and nine regulated activities. Why it matters: many companies manage compliance in silos, with a drug team, a device team and a natural health product team each maintaining its own procedures and its own reading of Health Canada's expectations. Version 10 removes the excuse for divergence, because the enforcement categories, the graduated response and the penalty provisions are the same regardless of the product.

What to do: run one cross-sector gap check rather than several disconnected ones, so that a stop-sale procedure written for your drug line and the one written for your device line say the same thing and meet the same standard. A firm that also imports should confirm that its border-hold response is consistent with the Canada Border Services Agency refusal power described in the policy, and a firm that distributes medical devices should align its recall procedure with the device-specific reporting timelines we cover in medical device recall reporting in Canada. Consistency across classes is itself a signal of a mature quality system, and it is the fastest way to reduce total remediation effort.

Compliance checklist: eleven documents to re-verify

Use this list to confirm your quality system reflects version 10. Each item is a document or procedure that commonly still references the old policy or the old assumptions.

• Inspection-response or host-an-inspector SOP, checked for any citation of version 9
• CAPA procedure and CAPA plan template, aligned to a request made during an inspection or a proposed suspension
• Recall SOP and recall decision procedure, including recall classification
• Stop-sale procedure, kept distinct from the recall procedure
• Complaint handling SOP that feeds compliance monitoring signals
• Adverse reaction and medical device incident reporting SOP
• Import compliance and border-hold response SOP, covering a Canada Border Services Agency refusal
• Terms and conditions management procedure for the establishment licence or product authorization
• Licence suspension or cancellation contingency and business continuity plan
• Regulatory change control and management review SOP, updated to capture version 10
• Document control index confirming the current policy version is the one your system cites

If several of these are weak, start with the two that inspectors read first: the CAPA system and the SOPs themselves. See why CAPA keeps failing on root cause and the ten SOPs every licensed facility gets wrong.

Common mistakes

• Treating version 10 as a drugs-only update when biocides, natural health products, veterinary products, blood and cells, tissues and organs are now expressly named
• Leaving inspection-response and CAPA procedures citing version 9 of the policy
• Assuming there is a transition period; the policy took effect the day it was published
• Confusing a stop-sale request with a recall order; they are separate tools with separate obligations
• Believing enforcement applies only to intentional non-compliance, when measures apply whether the failure is unintentional or intentional
• Underestimating exposure by quoting the general section 31 ceiling instead of the therapeutic product ceiling under section 31.2

Frequently asked questions

What is Health Canada POL-0001?

POL-0001 is Health Canada's compliance and enforcement policy for health products. It describes how the Regulatory Operations and Enforcement Branch promotes, monitors and enforces compliance with the Food and Drugs Act and its regulations. It is administrative, so the Act and the regulations always take precedence over the policy.

When did POL-0001 version 10 come into force?

Version 10 came into effect on 15 September 2026, the same day it was published, and it replaces version 9. There is no transition period, so any procedure that still references version 9 is now pointing to a superseded policy.

Does POL-0001 apply to natural health products and biocides?

Yes. Version 10 expressly names seven product classes in scope: biocides, blood and blood components, cells, tissues and organs, human drugs, medical devices, natural health products, and veterinary drugs and veterinary health products.

What enforcement actions can Health Canada take against a licence holder?

Actions range from public advisories and terms and conditions on a licence, to requesting a CAPA plan, requesting a stop sale or recall, border refusal through the Canada Border Services Agency, seizure and detention, licence suspension or cancellation, a court injunction, and referral to the Public Prosecution Service of Canada.

What is the difference between a stop sale and a recall order?

A stop sale halts further sale of a product, while a recall removes product that has already been distributed. Health Canada can request a stop sale or a recall, and can order a recall of a therapeutic product. They are distinct tools, and your procedures should treat them separately.

What are the penalties under section 31.2 of the Food and Drugs Act?

Section 31.2 covers offences relating to therapeutic products. On conviction by indictment, the penalty is a fine up to $5,000,000, or imprisonment up to two years, or both. It is a strict liability offence, so a due diligence defence is available.

Does the enforcement policy apply only to intentional non-compliance?

No. Health Canada may take enforcement measures where requirements are not met, whether the failure is unintentional or intentional. The severity of the response depends on the health and safety risk and the specifics of the case.

Is there a transition period to update our SOPs?

No transition period was provided; version 10 is already in force. The practical step is to run a focused gap check now against your inspection-response, CAPA and recall procedures, and update any document that still cites the previous version.

How MFLRC can help

MFLRC helps regulated companies turn a policy change into a short, defensible action list. For POL-0001 version 10 we run an inspection-readiness assessment benchmarked to the version 10 language, rebuild CAPA and root cause investigation programmes so they hold up under scrutiny, and test your recall system with a mock recall. We also carry out gap assessments across GMP, GPP, GUI-0158 and ISO 13485, develop and remediate SOPs and document control, and provide Quality Assurance Person support and regulatory change monitoring as a service. Our work spans all seven product classes now named in the policy, from pharmaceuticals and medical devices to natural health products, biocides, veterinary products and blood, cells and tissues.

If your inspection-response SOP still cites version 9, that is a small, fixable gap today and a finding tomorrow. Let us map version 10 against your quality system before it is ever tested.

Conclusion

Version 10 of POL-0001 did not change the law, but it changed the map. It states the scope more broadly, groups Health Canada's tools into three clear categories, confirms that enforcement graduates when non-compliance persists, and restates penalties that reach $5,000,000 for therapeutic product offences. The compliance task is straightforward and time-limited: confirm which version your quality system cites, re-verify the eleven documents above, and close any gap before your next inspection. Do that now, while it is a controlled internal exercise rather than a response to a finding.

Sources and references

• Health Canada, Compliance and enforcement policy for health products (POL-0001): Overview
• Health Canada, POL-0001: Compliance and enforcement actions and tools
• Health Canada, Compliance and Enforcement Policy Framework
• Food and Drugs Act (R.S.C., 1985, c. F-27), Justice Laws Website